Investor Alert: Shareholder Investigations
Brodsky & Smith is reaching out to inform investors about ongoing investigations concerning several corporations. If you hold shares in these entities and wish to talk about the investigations, please contact Jason Brodsky or Marc Ackerman by calling 855-576-4847. Assistance is provided without any costs or obligations.
Akero Therapeutics: Acquisition Overview
Akero Therapeutics, Inc. (NASDAQ: AKRO) has entered into an agreement where it will be acquired by Novo Nordisk A/S. The deal offers shareholders $54.00 in cash at closing, alongside a Contingent Value Right (CVR) worth $6.00 per share, pending regulatory approval for efruxifermin as a treatment for compensated cirrhosis due to MASH by a specifically set deadline. This investigation aims to determine whether the Akero Board met its fiduciary duties by ensuring a fair process and whether the offered compensation reflects fair value for shareholders.
CoreCard Corporation: Merger Insights
CoreCard Corporation (NYSE: CCRD) is set to undergo a transformative merger with Euronet (NASDAQ: EEFT) through a stock-for-stock agreement, bringing the total valuation to approximately $248 million. This agreement translates to a value of $30 per share for CoreCard’s common stock. The focus of this investigation is to understand whether the CoreCard Board upheld its fiduciary obligations by maintaining equitable practices during the merger discussions and ensuring the shareholders received appropriate value.
Air Lease Corporation: A Deep Dive
Air Lease Corporation (NYSE: AL) has agreed to be acquired by a holding entity connected with major investment firms, promising Air Lease stockholders $65.00 in cash per share of Class A common stock. This outstanding deal hints at a total valuation of around $7.4 billion. The investigation examines the Air Lease Board’s actions to ensure they conformed to their duty of care by facilitating a fair process and whether the merger deal presents sufficient value for its shareholders.
PB Bankshares, Inc.: Exploring the Deal
PB Bankshares, Inc. (NASDAQ: PBBK) is poised for acquisition by Norwood Financial Corp (NASDAQ: NWFL). In this merger, 80% of PB Bankshares’ common shares will transition to Norwood Financial common stock, while the remaining 20% will be converted to cash. Shareholders will have the option between cash payment or stock exchange, which will certainly influence their decision-making. The investigation looks into whether the PB Bankshares Board properly fulfilled their fiduciary responsibilities by conducting an equitable process and ensuring that shareholders experienced fair value.
About Brodsky & Smith
Brodsky & Smith is recognized for its strong expertise in representing shareholders across the country in securities and class action litigation. The firm has been entrusted by numerous courts to serve as lead counsel in various cases and has successfully secured millions of dollars for clients and shareholders. Prior results do not guarantee similar outcomes in future cases.
Frequently Asked Questions
What companies are under investigation?
The investigation covers Akero Therapeutics, CoreCard Corporation, Air Lease Corporation, and PB Bankshares, Inc.
What is the focus of the investigations?
The investigations primarily concern whether the respective boards of these companies fulfilled their fiduciary duties during acquisition negotiations.
Who can I contact for more information?
Investors can reach out to Jason Brodsky or Marc Ackerman at Brodsky & Smith by calling 855-576-4847.
Are there any costs associated with participating in these investigations?
No, there are no costs or financial obligations involved for the investors.
What potential outcomes can shareholders expect?
While the investigations aim to ensure fair practices, specific outcomes depend on the findings related to fiduciary duties and board processes.
